CREATE Medicines' In Vivo CAR-T Platform Achieves Full B Cell Depletion in Non-Human Primates CREATE Medicines has unveiled groundbreaking data demonstrating complete B cell depletion in non-human primates, showcasing its in vivo CAR-T platform's potential.

CREATE Medicines' In Vivo CAR-T Platform Achieves Full B Cell Depletion in Non-Human Primates #USA #Cambridge #biotechnology #CAR-T_therapy #CREATE_Medicines

CREATE Medicines to Showcase Innovative CAR Therapy at J.P. Morgan Healthcare Conference CREATE Medicines will present groundbreaking updates in CAR therapy at the 44th Annual J.P. Morgan Healthcare Conference, highlighting significant clinical advancements.

CREATE Medicines to Showcase Innovative CAR Therapy at J.P. Morgan Healthcare Conference #United_States #San_Francisco #J.P._Morgan #CAR_therapy #CREATE_Medicines

CREATE Medicines Administers First Dose as Part of Pioneering HCC Trial for Innovative CAR Therapy CREATE Medicines has initiated patient dosing in a groundbreaking clinical trial assessing MT-303, a novel CAR therapy combined with standard immunotherapy for liver cancer treatment.

CREATE Medicines Administers First Dose as Part of Pioneering HCC Trial for Innovative CAR Therapy #United_States #Cambridge #CREATE_Medicines #HCC_Trial #MT-303

CREATE Medicines Achieves Groundbreaking First-in-Human Results for MT-302 Immunotherapy Trial CREATE Medicines has announced promising first-in-human results for its MT-302 immunotherapy, demonstrating effective tumor targeting and manageable safety in patients.

CREATE Medicines Achieves Groundbreaking First-in-Human Results for MT-302 Immunotherapy Trial #United_States #Cambridge #Immunotherapy #CREATE_Medicines #MT-302

CREATE Medicines to Showcase Innovative MT-302 Data at SITC Annual Meeting CREATE Medicines is set to unveil pivotal clinical data on MT-302 during the SITC 40th Annual Meeting, highlighting groundbreaking CAR therapy for solid tumors.

CREATE Medicines to Showcase Innovative MT-302 Data at SITC Annual Meeting #USA #National_Harbor,_Maryland #CAR_therapy #CREATE_Medicines #MT-302

CREATE Medicines Launches Innovative RetroT T-Cell Engineering Platform for Safer Gene Therapy CREATE Medicines has unveiled RetroT, a groundbreaking RNA-based system for T-cell engineering that enables precise, durable gene integration without DNA damage, revolutionizing cancer therapies.

CREATE Medicines Launches Innovative RetroT T-Cell Engineering Platform for Safer Gene Therapy #United_States #Cambridge #CREATE_Medicines #RNA-based_therapy #T-Cell_Engineering

CREATE Medicines and Amsterdam University Medical Center Launch In Vivo CAR Therapy Trial for Solid Tumors CREATE Medicines and Amsterdam UMC have commenced a pivotal trial for an innovative in vivo CAR therapy, MT-302, targeting advanced gastroesophageal cancer with promising combination treatments.

CREATE Medicines and Amsterdam University Medical Center Launch In Vivo CAR Therapy Trial for Solid Tumors #United_States #Cambridge #CREATE_Medicines #MT-302 #Amsterdam_UMC

CREATE Medicines Enhances Leadership Team with Allan L. Shaw as CFO and CBO CREATE Medicines has announced the addition of veteran biopharma leader Allan L. Shaw as its new CFO and CBO. His experience is expected to drive the company's growth.

CREATE Medicines Enhances Leadership Team with Allan L. Shaw as CFO and CBO #United_States #Cambridge #CREATE_Medicines #Allan_L._Shaw #biopharma_leadership

CREATE Medicines: Revolutionizing Immunotherapy with RNA-Based Multi-Immune Programming CREATE Medicines is redefining immunotherapy through innovative RNA-based multi-immune programming, expanding treatment options and improving patient outcomes.

CREATE Medicines: Revolutionizing Immunotherapy with RNA-Based Multi-Immune Programming #USA #Cambridge #Immunotherapy #RNA_Therapy #CREATE_Medicines